Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...
However, commercial farmers say that vaccine shortages and slow implementation are worsening a devastating crisis ...
In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and commercial attractivenessSaint Herblain (France), January 19, ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. While the media's attention has focused on unproven links between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results